Experience

Faculty Appointments

Adjunct Faculty, College of Pharmacy,
Marshall B. Ketchum University, 2018

Adjunct Faculty, David Geffen School of Medicine at UCLA 2017-now

Clinical Assistant Professor, College of Pharmacy,
Oregon State University/Oregon Health Sciences University, 2011-2013

Graduate Education

Post-Doctoral Infectious Diseases Outcomes Pharmacotherapy Fellowship (Ph.D)
Wayne State University, Anti-Infective Research Laboratory, 2008-2011

Masters of Public Health (M.P.H) in Biostatistics and Epidemiology,
Wayne State University School of Medicine, 2008-2012

Making a Difference in Infectious Diseases (MAD-ID),
Advanced Antimicrobial Stewardship Certification

National Institute of Health (NIH) Grant Writing Workshop,
Wayne State University, 2008

Publications

Kullar R, Frisenda J, Nassif PS. The More the Merrier? Should Antibiotics be Used for Rhinoplasty and Septorhinoplasty?—A Review. Plastic and Reconstructive Surgery – Global Open. 2018 October; 6(10): e1972.
DOI: 10.1097/GOX.0000000000001972

Kullar R, Nagel J, Bleasdale SC, Sutton SH, Naumovski S, Rodriguez A, Smith C, Leggett J, Goldstein EJC. Going for the Gold: A Description of ‘Centers of Excellence’ Designation by Infectious Diseases Society of America. Clinical Infectious Diseases 2018 Sep 18.
DOI: 10.1093/cid/ciy797

Co-author with National Quality Forum. Antibiotic Stewardship in Post-Acute and Long-Term Care Playbook.

Kullar R, Yang H, Grein J, Murthy R.  A Roadmap to Implementing Antimicrobial Stewardship Principles in Long-Term Care Facilities (LTCFs): Collaboration Between an Acute-Care Hospital and LTCFs.  (Invited Article).  Clinical Infectious Diseases 2018 Apr 3;66(8):1304-1312. DOI: 10.1093/cid/cix1041

Goff DA, Kullar R, Bauer K, File T.  Eight Habits of Highly Effective Antimicrobial Stewardship Programs to Meet the Joint Commission Standards for Hospitals. (Invited Article). Clinical Infectious Diseases 2017 Apr 15;64(8):1134-1139. DOI: 10.1093/cid/cix065

Xiao AJ, Caro L, Popejoy MW, Huntington JA, Kullar R.  PK/PD Target Attainment With Ceftolozane/Tazobactam Using Monte Carlo Simulation in Patients With Various Degrees of Renal Function, Including Augmented Renal Clearance and End-Stage Renal Disease. Infect Dis Ther. 2017 March; 6 (1): 137-148.

Kullar R., Wagenlehner F., Popejoy M.W., Long J., Yu B., Goldstein E.J.  Does Moderate Renal Impairment Affect Clinical Outcomes in Complicated Intra-Abdominal and Complicated Urinary Tract Infections? – Analysis of Two Randomized, Controlled Trials with Ceftolozane/Tazobactam.  Journal of Antimicrobial Chemotherapy.  2016 Dec 20.

Goff DA, Kullar R, Goldstein EJ, Gilchrist M, Nathwani D, Cheng AC, Cairns KA, Escandón-Vargas K, Villegas MV, Brink A, van den Bergh D, Mendelson M.  A Global Call From Five Countries to Collaborate in Antibiotic Stewardship: United We Succeed, Divided We Might Fail. (Invited Article). Lancet Infect Dis. 2016 Nov 17. DOI: https://doi.org/10.1016/S1473-3099(16)30386-3

Kullar R, Sakoulas G, Deresinksi S, van Hal SJ. When Sepsis Persists: A Review of MRSA Bacteraemia Salvage Therapy.  (Invited Article). J Antimicrob Chemother 2016 Mar; 71 (3) 576-86.

Kullar R, Vassallo A, Turkel S, Chopra T, Kaye KS, Sobrah Dhar.  “Degowning” the Controversies of Contact Precautions (CP) for Methicillin-Resistant Staphylococcus aureus (MRSA): A Review.  (Invited Article). American Journal of Infection Control 2016 Jan 1; 44 (1): 97-103.

Casapao AM, Lodise TP, Davis S, Claeys KC, Kullar R, Levine DP, Rybak MJ.  The Association between the Vancomycin Day 1 Exposure Profile and Outcomes Among Patients with Methicillin-Resistant Staphylococcus aureus Infective Endocarditis. Antimicrobial Agents of Chemotherapy 2015; 59 (6): 2978-85.

Goff DA, Kullar R, Newland JG.  Review of Twitter for Infectious Diseases Clinicians: Useful or a Waste of Time?  (Invited Article). Clinical Infectious Diseases 2015 May 15; 60 (10): 1533-40. DOI:10.1093/cid/civ071

Sakoulas G, Nonejuie P, Kullar R, Pogliano J, Rybak M, Nizet V.  Examining the Use of Ceftaroline in the Treatment of Streptococcus pneumoniae Meningitis with Reference to Human Cathelicidin LL-37.  Antimicrobial Agents of Chemotherapy 2015 April; 59(4): 2428-31.

Kullar R., McKinnell J.A., Sakoulas G. Avoiding the Perfect Storm: The Biologic and Clinical Case for Reevaluating the 7-Day Expectation for Methicillin-Resistant Staphylococcus aureus Bacteremia Before Switching Therapy. (Invited Article). Clinical Infectious Diseases 2014 Nov 15;59(10):1455-61.

Forrest GN, Van Schooneveld TC, Kullar R, Schulz LT, Duong P, Postelnick M.  Use of Electronic Health Records and Clinical Decision Support Systems for Antimicrobial Stewardship.  Clinical Infectious Diseases 2014 Oct 15;59 Suppl 3:S122-33. DOI: 10.1093/cid/ciu565

Sakoulas G, Moise PA, Casapao AM, Nonejuie P, Olson J, Okumura CY, Rybak MJ, Kullar R, Dhand A, Rose WE, Goff DA, Bressler AM, Lee Y, Pogliano J, Johns S, Kaatz GW, Ebright JR, Nizet V.  Antimicrobial Salvage Therapy for Persistent Staphylococcal Bacteremia using Daptomycin plus Ceftaroline.  Clinical Therapeutics 2014 Oct 1;36(10):1317-33.

Casapao A, Davis S, McRoberts J, Lagnf A, Patel S, Kullar R, Levine D, Rybak M. Evaluation of Vancomycin Population Analysis Profile Susceptibility as a Predictor of Patient Outcomes with Methicillin-Resistant Staphylococcus aureus Infective Endocarditis. Antimicrobial Agents of Chemotherapy 2014 Aug; 58(8): 4636-41.

Kullar R., Goff D.A.  Transformation of Antimicrobial Stewardship Programs through Technology.  (Invited Article and chapter in book).  Infectious Disease Clinics of North America 2014 Jun; 28(20): 291-300. DOI: 10.1016/j.idc.2014.01.009

Kullar R., McClellan I., Geriak M., Sakoulas G. Efficacy and Safety of Daptomycin in Patients with Renal Impairment: A Multicenter Retrospective Analysis. Pharmacotherapy 2014 Jun; 34(6): 582-9.

Kullar R., Casapao A, Davis SL, Levine DP, Zhao J, Crank C, Segreti J, Sakoulas G,  Cosgrove S; Rybak MJ. A Multicentre Evaluation of the Effectiveness and Safety of High-Dose Daptomycin for the Treatment of Infective Endocarditis.  Journal of Antimicrobial Chemotherapy 2013 Dec; 68(12): 2921-6.

Bubalo J., Kullar R., Maziarz R.  A Pilot Study of the Efficacy and Safety of Empiric Daptomycin Therapy in Oncology Patients with Fever and Severe Neutropenia. Therapeutic Advances in Infectious Disease 2013 Dec; 1(6): 183-90.

Casapao A., Kullar R., Davis SL, Levine DP, Zhao J, Potoski B, Goff D, Crank C, Segreti J, Sakoulas G, Rybak MJ.  Multicenter Study of High-Dose Daptomycin for Treatment of Enterococcal Infections. Antimicrobial Agents of Chemotherapy 2013 Sep; 57(9): 4190-6.

Kullar R., Goff D.A., Schulz LT, Fox B.C., Rose W.E.  The “Epic” Challenge of Optimizing Antimicrobial Stewardship: the Role of Electronic Medical Records and Technology. (Invited Article).  Clinical Infectious Diseases 2013 Oct; 57(7): 1005-13. DOI: 10.1093/cid/cit318

Kullar R., Rybak M.J., Kaye K.S.  Comparative Epidemiology of Bacteremia due to Methicillin-Resistant Staphylococcus aureus (MRSA) Between Older and Younger Adults: a Propensity Score Analysis. Infection Control and Hospital Epidemiology 2013 April; 34 (4): 400-6.

Murray K.P., Zhao J.J., Davis S.L., Kullar R., Kaye K.S., Lephart P., Rybak M.J. Early Use of Daptomycin Versus Vancomycin for Methicillin-Resistant Staphylococcus aureus Bacteremia With Vancomycin Minimum Inhibitory Concentration >1 mg/L: A Matched Cohort Study.  Clinical Infectious Diseases 2013 June; 56 (11): 1562-9.

Levine P.J., Elman M.R., Kullar R., Townes J.M., Bearden D.T., Vilches-Tran R., McClellan I., McGregor J.C.  Use of Electronic Health Record Data to Identify Skin and Soft Tissue Infections in Primary Care Settings: a Validation Study. BMC Infectious Diseases 2013 April 10; 13 (1): 171.

Kullar R., Davis S.L., Kaye K.S., Levine D.P., Pogue J., Rybak M.J.  Implementation of an Antimicrobial Stewardship Pathway with Daptomycin for Optimal Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia.  Pharmacotherapy 2013 January; 33(1): 3-10.

Kullar R., Davis S.L., Kaye K.S., Taylor T.N., Rybak M.J.  Evaluation of targeting higher vancomycin troughs on costs and clinical outcomes in a matched cohort of patients. Pharmacotherapy 2012; 32 (2).

Kullar R., Davis S.L., Levine D.P., Rybak M.J. Impact of vancomycin exposure on outcomes of patients with MRSAB: Verification of consensus guidelines suggested targets. Clinical Infectious Diseases 2011; 52 (8): 975-81.

Kullar R., Chin J.N., Edwards D.J., Coplin W.M., Parker D., Rybak M.J.  Central nervous system penetration and pharmacodynamics of daptomycin in neurological infections. Antimicrobial Agents of Chemotherapy 2011; 55 (7): 3505-9.

Kullar R., Leonard S., Davis S., Delgado G., Wahby K., Pogue J., Falcione B., Rybak M.J. Validation of a high-trough vancomycin nomogram to achieve trough concentrations of 15 to 20 mg/L.  Pharmacotherapy 2011; 31 (5): 441-48.

Kullar R., Davis S.L., Levine D.P., Zhao J., Crank C.W., Segreti J., Sakoulas G., Cosgrove S.E., Rybak M.J.  Large multi-center case-series analysis of high-dose daptomycin for complicated Gram-positive infections. Pharmacotherapy 2011; 31 (6): 527-36.

Honors and Awards

Honored as Fellow of Infectious Diseases Society of America (FIDSA); 2018

Invited TED Speaker; “The Antibiotic Resistance Crisis: How to be a Part of the Solution”, TEDxDetroit; 2018

Invited TED Speaker; “Understanding the crisis and how you can prevent a future pandemic”; 2018

Awarded as Who’s Who in the World-Albert Nelson Marquis Lifetime Achievement Award, 2018

Invited to United Nations General Assembly Meeting on Antimicrobial Resistance — Forum on Sustainable Access to Effective Antibiotics

  • September 2016
  • Recognized as global infectious diseases leader

Oregon Terra Magazine

  • Highlighted as researcher at OSU/OHSU in feature article in Oregon magazine

Society of Infectious Diseases (SIDP) Infectious Diseases Impact Paper of the Year.

  • Awarded for paper entitled “Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: Support for consensus guidelines suggested targets” published in Clinical Infectious Diseases
  • The purpose of this prestigious award is to “recognize a significant contribution to the peer-reviewed literature in infectious diseases pharmacotherapy.”
  • Presented at annual meeting in September 2011 in Chicago, IL

George McCracken Infectious Diseases Fellows Travel Grant through American Society for Microbiology (ASM) for Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).  Awarded 2010.

Infectious Diseases Society of America (IDSA) Fellows Travel Grant.  Awarded 2009.

Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Fellows Travel Grant.  Awarded 2009.

Abstracts,
Posters,
Invited Presentations

Kullar R. Becoming a Steward in Long-Term Care Facilities; Invited Speaker for MAD-ID Online Antimicrobial Stewardship (AMS) Teaching Modules; November 2018.

Kullar R. The Antibiotic Resistance Crisis: How to be a part of the solution; Invited TED Speaker; September 26, 2018; Detroit, MI https://youtu.be/JS6_UplxNc0

Kullar R. Understanding the crisis and how you can prevent a future pandemic; Invited TED Speaker; March 31, 2018; Bend, OR. https://youtu.be/tGtYvQCSfFA

Jayakumar R., Leuthner K., Kullar R., Puzniak L. Real-world evaluation of ceftolozane/tazobactam (C/T) in severely ill patients with sepsis and/or bacteraemia. Accepted poster ECCMID (Abstract #6855); April 21-24, 2018; Madrid, Spain

Kullar R. Antibiotic Resistance: Understanding the crisis and how you can prevent a future pandemic; Invited TED Speaker; March 31, 2018; Bend, OR

Kullar R. Invited speaker for Infectious Diseases Association for California (IDAC). How to Meet The Joint Commission (TJC) 8 Antimicrobial Stewardship Standards. Berkeley, CA; March 3, 2018.

Kullar R. Invited speaker for Los Angeles Department of Public Health – Antibiotics Awareness Week. Meeting The Joint Commission 8 Antimicrobial Stewardship Standards and Overcoming Common Barriers in Your Stewardship Program. Los Angeles, CA; November 13, 2017.

Yang H., Kullar R., Grein J., Murthy R. Partners in Stewardship: Collaboration Between a Tertiary Hospital and Local Skilled Nursing Facilities to Improve Management of Suspected Urinary Tract Infections. Accepted poster ID Week; October 4-8, 2017; San Diego, CA

Leuthner K.D., Kullar R., Jayakumar R., Hewlett D.A, Nguyen T., Puzniak L. Real World Evaluation of Ceftolozane/Tazobactam (C/T) Use and Clinical Outcomes at an Academic Medical Center in Las Vegas. Accepted poster ID Week; October 4-8, 2017; San Diego, CA

Davis A., Hermsen E.D., Kullar R., Oakley L., Roberts Y., Puzniak LA. Impact of Use of Fidaxomicin (FDX) in a Treatment Algorithm for Clostridium difficile Infection (CDI) in Hospitalized Patients at High Risk for Recurrence. Wellstar Hlth.System, Austell, GA, Merck & Co., Inc., Kenilworth, NJ. Accepted poster American Society for Microbiology (ASM); June 1-6, 2017; New Orleans, LA

Kullar R., Rastogi A., Saidian J., Li A., Asaturyan A., Hanna M., Joseph E., Puzniak L. Treatment management and outcomes in patients with Clostridium difficile infection (CDI): assessing the impact of renal disease. Accepted poster European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); April 22-25, 2017; Vienna, Austria

Rastogi A., Kullar R., Alipourfetrati S., Arman F., Hanna H.S., Faiek S., Puzniak L. The Interplay between Clostridium difficile Infection (CDI) and Renal Disease: Epidemiology, Treatment Management and Outcomes. Division of Nephrology, Dept of Medicine, University of California, Los Angeles, Los Angeles, CA; Center of Observational and Real World Evidence, Merck & Co, Inc, Kenilworth, NJ. Accepted poster American Society of Nephrology; November 15-20; Chicago, IL

Kullar R., Merchant S., Tabak Y.P., et al. Regional and Source Variations in Vancomycin-resistant Enterococci (VRE) Rates in US Hospitals 2015. Accepted poster Infectious Disease (ID) Week; October 27, 2016

Kullar R., De Anda C., Anuskiewicz S., Prokocimer P. Outpatient Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSI) with Tedizolid Phosphate and Linezolid in Patients in the United States. Accepted poster Antimicrobial Society of Microbiology (ASM) Microbe; June 18, 2016

Kullar R. Invited speaker for Infectious Diseases Association for California (IDAC). Components of an Effective ASP Informatics Program: Essential Elements and Helpful Enhancements. Berkeley, CA; March 4, 2016.

Kullar R. Invited speaker for Infectious Diseases Association for California (IDAC). Components of an Effective ASP Informatics Program: Essential Elements and Helpful Enhancements. Irvine, CA; July 18, 2015.

Kullar R. Invited speaker for Infectious Diseases Association for California (IDAC). Electronic health records (EHRs) and the I.D. clinician. Oakland, CA; March 15, 2014.

Kullar R. Invited speaker for Association for Professionals in Infection Control and Epidemiology (APIC). The role of rapid diagnostics in antimicrobial stewardship. Los Angeles, CA; February 25, 2014.

Kullar R., Markwardt S., Forrest G. Epidemiology and Treatment of Vancomycin-Resistant Enterococcal Infections: Efficacy and Safety Comparison of Daptomycin and Linezolid. Poster presentation at ECCMID April 27-30, 2013; Berlin, Germany.

Kullar R. Overuse of Antibiotics and the Evolution of a new Superbug, Clostridium difficile; Oregon Academy of General Dentistry (OAGD). 2012 meeting October 13, 2012; Newburg, OR.

Kullar R., McClellan I., Geriak M., Sakoulas G. Efficacy and Safety of Daptomycin in the Treatment of Gram-Positive Infections in Patients with Renal Impairment. Poster presentation at ICAAC September 8-12, 2012; San Francisco, CA.

Kullar R., Rybak M.J., Kaye K.S. Comparative Epidemiology of Bacteremia due to Methicillin-Resistant Staphylococcus aureus (MRSA) Between Older and Younger Adults: A Propensity Score Analysis. Poster presentation at ICAAC September 8-12, 2012; San Francisco, CA.

Kullar R., Garber J., Alhadab A., Olyaei A., Allada G., Gold J., Munar M.J. Piperacillin-Tazobactam (PT) Extended Infusion (EI) Therapy to Treat Pulmonary Exacerbations in Patients with Cystic Fibrosis. Poster presentation at ICAAC September 8-12, 2012; San Francisco, CA.

Casapao A., Kullar R., Patel S., Rybak M.J. Evaluation of Population Analysis Profile Susceptibility (PAP) as a Predictor of Patient Outcomes with Methicillin-Resistant Staphylococcus aureus (MRSA) Infective Endocarditis (IE). Poster presentation at ICAAC September 8-12, 2012; San Francisco, CA.

Casapao A., Kullar R., Davis S.L., Levine D.P., Zhao J., Goff D., Sakoulas G.,Cosgrove S.E., Rybak M.J. High-Dose Daptomycin for Treatment of Enterococcal Infections: Multicenter, Retrospective Study. Poster presentation at ICAAC September 8-12, 2012; San Francisco, CA.

Murray K.P., Kullar R., Davis S.L., Rybak M.J. Daptomycin vs. vancomycin MIC > 1 mg/L in a matched cohort of patients with MRSAB. Platform presentation at ICAAC September 8-12, 2012; San Francisco, CA.

Kullar R. The Hidden Costs of Treating MRSA: Economic and Clinical Implications. Invited speaker annual Oregon Society of Health-System Pharmacists (OSHP) 2012 meeting April 18-20, 2012; Sunriver, OR.

Kullar R., Chin J.N., Parker D., Coplin W.M., Edwards D.J., Rybak M.J. Central nervous system penetration and pharmacokinetcs of daptomycin in neurological infections. Platform presentation at ICAAC September 12-15, 2010; Boston, MA.

Kullar R., Davis S.L., Pogue J.M., Zhao J.J., Levine D.P., Kaye K.S., Rybak M.J. Evaluation of a clinical pathway for the treatment of MRSA bacteremia with an MIC of >1 mg/L to vancomycin. Poster presentation at ICAAC September 12-15, 2010; Boston, MA.

Kullar R., Davis S.L., Levine D.P., Rybak MJ. Vancomycin trough concentrations and outcomes in patients with MRSA infective endocarditis. Poster Walk Oral presentation at ICAAC September 12-15, 2010; Boston, MA.

Kullar R., Davis S.L., Levine D.P., Zhao J.J., Crank C.W., Cosgrove S.E., Segreti J., Rybak M.J. High-dose daptomycin for infective endocarditis. Platform presentation at ECCMID April 10-13, 2010; Vienna, Austria.

Kullar R., Davis S.L., Kaye K.K., Taylor T., Rybak M.J. Cost and outcome implications of the newly developed high-dose vancomycin consensus guidelines. Poster presentation at ECCMID April 10-13, 2010; Vienna, Austria. Abstract # 2772; Encore presentation at MAD-ID May 6-8, 2010; Orlando, FL.

Kullar R., Davis S.L., Levine D.P., Zhao J.J., Crank C.W., Cosgrove S.E., Segreti J., Rybak M.J. High-dose daptomycin for enterococcal infections. Poster presentation at IDSA October 29-November 1, 2009; Philadelphia, PA. Abstract # 895.

Kullar R., Davis S.L., Levine D.P., Zhao J.J., Crank C.W., Cosgrove S.E., Segreti J., Rybak M.J. Safety of high-dose daptomycin for Gram-positive infections. Poster presentation at ICAAC September 12-15, 2009; San Francisco, CA. Abstract # 1983.

Kullar R., Bhan R., Davis S.L., Rybak M.J. Outcomes of patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Platform presentation at ICAAC September 12-15, 2009; San Francisco, CA.

Kullar R., Davis S.L., Levine D.P., Zhao J.J., Crank C.W., Cosgrove S.E., Segreti J., Rybak M.J. High-dose daptomycin for complicated Gram-positive infections. Poster presentation at ECCMID May 16-20, 2009; Helsinki, Finland. Abstract #P1986; 6th Annual Research Forum Eugene Applebaum College of Pharmacy and Health Sciences September 9, 2009.

Patel S., Kullar R., Davis S.L., Steed M.E., Rybak M.J. Evaluation of population analysis profile susceptibility as a predictor of patient outcome in patients with MRSA infective endocarditis. Poster presentation at the 6th Annual Research Forum Eugene Applebaum College of Pharmacy and Health Sciences September 9, 2009.

Kullar R., Leonard S., Davis S., Delgado G., Wahby K., Pogue J., Sheth A., Shah P., Falcione B., Rybak M. Validation of a high-trough vancomycin nomogram to achieve trough concentrations of 15 to 20 mg/L. Poster presentation at ECCMID May 16-20, 2009; Helsinki, Finland. Abstract # P1982.

Kullar R., Davis S., Rybak M. New vancomycin guidelines in relationship to patients with MRSA bacteremia. Poster Presentation at Staphylococcus Symposium March 11-14, 2009; Honolulu, Hawaii.

Kullar R., Davis S.L., Rybak M.J., Kaye K.S. Comparative epidemiology of MRSA bacteremia between older and younger adults. Poster presentation at SHEA March 19-22, 2009; San Diego, CA.

As featured on:

Contact Dr. Ravina Kullar

Contact Dr. Ravina Kullar

© 2018 RAVINA KULLAR. ALL RIGHTS RESERVED. DESIGNED & DEVELOPED BY S3SB
PRIVACY POLICY